Scientists Find Targeting Enzyme That Could Block Brain Metastases
Researchers from King’s College London and McMaster University have made a discovery that could fundamentally change how doctors treat brain cancer. The team identified a molecular pathway that appears critical to cancer’s ability to migrate to the brain.
Working with a commercial partner called Block Biosciences, they created drug candidates designed to block this process. This work represents a shift from treating cancer after it spreads to preventing that spread in the first place.
The enzyme, IMPDH2, which appears in two separate versions within human cells, emerged as the key target for intervention. Only one version plays a role in brain metastatic tumor development. Crucially, this version is abundant in cancer cells but nearly absent in healthy tissue.
That distinction is what makes IMPDH2 so attractive to researchers seeking safer drug options. Sheila Singh, lead author and professor of neuro-oncology and neurosurgery at both universities, has spent years pursuing a different strategy. She and her colleagues focused on spotting patients who might develop this disease before symptoms emerge.
Singh’s vision centers on finding vulnerable patients before the disease strikes and stopping cancer cells before they colonize the brain. She believes this approach could prevent what is currently a nearly universal death sentence from taking hold.
Previous attempts to block IMPDH as a drug target had failed. These drugs damaged normal cells while attacking cancerous ones, making them too toxic for patients. The side effects were severe enough to halt clinical use. By targeting IMPDH2 exclusively, Singh’s group theorized they could avoid this toxicity problem.
Brain tumors that begin elsewhere and migrate to the brain represent one of the most serious forms of cancer. The outlook for patients is bleak, with roughly 90% of patients not living past one year after diagnosis, Singh says. Existing treatments focus mainly on managing pain and symptoms rather than stopping the disease itself, and clinicians have long lacked effective tools for prevention.
After the McMaster team and Block Biosciences chemists synthesized many potential drug molecules, researchers screened these molecules to identify which show the most promise for safety and effectiveness.
The most promising compounds are moving forward into clinical testing. While timelines remain unpredictable, the preliminary results have encouraged continued development.
The significance of this research extends well beyond this single disease as modern cancer treatment has long operated on a reactive model. Doctors identify a tumor, then treat it as aggressively as possible. This approach has severe limitations when cancer has already spread and often has lower survival outcomes.
If clinical trials bear this out, it could revolutionize how oncologists approach metastatic disease and increase the survival rates of various cancer types. Meanwhile, other entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also hitting major milestones in their quest to bring the next generation of brain cancer medications onto the market. With time, malignancies affecting the central nervous system could lose their grim prognosis if more effective treatments become available.
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer
Researchers from King’s College London and McMaster University have made a discovery that could fundamentally change how doctors treat brain cancer. The team identified a molecular pathway that appears critical to cancer’s ability to migrate to the brain.
Working with a commercial partner called Block Biosciences, they created drug candidates designed to block this process. This work represents a shift from treating cancer after it spreads to preventing that spread in the first place.
The enzyme, IMPDH2, which appears in two separate versions within human cells, emerged as the key target for intervention. Only one version plays a role in brain metastatic tumor development. Crucially, this version is abundant in cancer cells but nearly absent in healthy tissue.
That distinction is what makes IMPDH2 so attractive to researchers seeking safer drug options. Sheila Singh, lead author and professor of neuro-oncology and neurosurgery at both universities, has spent years pursuing a different strategy. She and her colleagues focused on spotting patients who might develop this disease before symptoms emerge.
Singh’s vision centers on finding vulnerable patients before the disease strikes and stopping cancer cells before they colonize the brain. She believes this approach could prevent what is currently a nearly universal death sentence from taking hold.
Previous attempts to block IMPDH as a drug target had failed. These drugs damaged normal cells while attacking cancerous ones, making them too toxic for patients. The side effects were severe enough to halt clinical use. By targeting IMPDH2 exclusively, Singh’s group theorized they could avoid this toxicity problem.
Brain tumors that begin elsewhere and migrate to the brain represent one of the most serious forms of cancer. The outlook for patients is bleak, with roughly 90% of patients not living past one year after diagnosis, Singh says. Existing treatments focus mainly on managing pain and symptoms rather than stopping the disease itself, and clinicians have long lacked effective tools for prevention.
After the McMaster team and Block Biosciences chemists synthesized many potential drug molecules, researchers screened these molecules to identify which show the most promise for safety and effectiveness.
The most promising compounds are moving forward into clinical testing. While timelines remain unpredictable, the preliminary results have encouraged continued development.
The significance of this research extends well beyond this single disease as modern cancer treatment has long operated on a reactive model. Doctors identify a tumor, then treat it as aggressively as possible. This approach has severe limitations when cancer has already spread and often has lower survival outcomes.
If clinical trials bear this out, it could revolutionize how oncologists approach metastatic disease and increase the survival rates of various cancer types. Meanwhile, other entities like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also hitting major milestones in their quest to bring the next generation of brain cancer medications onto the market. With time, malignancies affecting the central nervous system could lose their grim prognosis if more effective treatments become available.
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer
